

PHARMACEUTICAL SCIENCES



Received on 24 April, 2017; received in revised form, 07 July, 2017; accepted, 17 September, 2017; published 01 January, 2018

ANALYSIS OF VARIABLES INVOLVE IN RHEUMATOID ARTHRITIS DIAGNOSIS USING LOGISTIC REGRESSION

Ausaf Ahmad*1, T. B. Singh 1, Usha 2 and Navin Kumar 1

Division of Biostatistics ¹, Department of Community Medicine, Department of Pathology ², Institute of Medical Sciences, Banaras Hindu University, Varanasi - 221005, Uttar Pradesh, India.

Keywords:

Epidemiological, Cross-sectional, Rheumatoid arthritis, Autoimmune

Correspondence to Author: Ausaf Ahmad

Research Scholar, Division of Biostatistics, Department of Community Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi - 221005, Uttar Pradesh, India.

E-mail: ausafahmad86@gmail.com

ABSTRACT: Rheumatoid Arthritis (RA) is a auto-immune disease in which body mistakenly considers some parts of its own system as pathogens and attacks them. RA is a chronic systemic inflammatory illness with prevalence of approximately 0.75% in India. It leads to irreversible joint damage and systemic complications. It is associated with substantial morbidity and increased mortality Better understanding of its pathophysiology has led to the progress of besieged therapies that have significantly enhanced outcomes. The key to beneficial achievement lies in identifying those who will have rigorous critical disease as early as possible, so that efficient management can be initiated prior to unalterable injure occurs. The primary aim of this study is to find out what factors play a significant role in determine the disease. From the brief account of discussion on observation and results of multivariate techniques are established, such techniques are important for they make it possible to encompass all the data from an investigation in one analysis. They in fact result in a clearer and better account of the research effort than do the piecemeal analyses of portions of data. Anti-cyclic citrullinated peptide (anti-CCP) antibody testing is mostly useful in the diagnosis of rheumatoid arthritis, with high specificity, presence early in the disease process, and ability to identify patients who are likely to have severe disease and unalterable injure. As of this observation concluded that disease also affects the quality of life *i.e.* disablement enhances.

INTRODUCTION: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease characterized by a distinctive pattern of bone and joint destruction. RA is also a systemic disease, and several patient subsets can be distinguished based on the presence of extra-articular manifestations. For example, the concomitant presence or absence of anti-cyclic citrullinated peptide antibody (ACPA) and rheumatoid factor (RF) defines two important patient subsets ¹.



DOI: 10.13040/IJPSR.0975-8232.9(1).123-32

Article can be accessed online on: www.ijpsr.com

DOI link: http://dx.doi.org/10.13040/IJPSR.0975-8232.9(1).123-32

Several epidemiological studies of RA have been published. They show variations in the incidence and prevalence of RA across populations. Further variation occurs as a result of differences in statistical methods and case-ascertainment criteria. Several large prospective studies have improved our knowledge of the risk factors for RA. Unfortunately, the available epidemiological data often come from retrospective studies and underpowered case—control studies.

In addition, the effects of several environmental factors on the risk and outcome of RA have been studied. Environmental factors that affect RA may act many years before the disease becomes clinically apparent ². While genetic factors contribute 50% to 60% of the risk of developing RA.

The gene most strongly associated with RA is the HLA-DRB1 gene in the major histocompatibility specificalleles complex. where within DRB1*04 and *01 clusters encode the "share depitope" sequences within the expressed DRB1 molecule. Rheumatoid arthritis, are the number one cause of early retirement, disability payments, and loss of employment ⁴. The social and economic consequences for the individual are drastic even in the first years of the disease. Within seven years, up to 40 percent of patients are no longer able to work in their profession ⁵. According to the WHO, this percentage rises significantly as rheumatoid arthritis progresses: ten years after onset of the disease, nearly 60 percent of RA patients are no longer able to work ⁶.

It is now accepted that those affected by these diseases must be genetically predisposed toward them. Many autoimmune diseases occur more frequently within families, and in some families there is an increased tendency toward autoimmune diseases ⁷. For some autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, the genetic component of the disease has already been scientifically verified ⁸⁻¹⁰. The primary aim of this study is to find out what factors play a significant role in determine the disease.

MATERIALS AND METHODS: This was a cross-sectional observational study. The study was carried out from between August 2012 and

February 2014 in UGC Advanced Immuno-diagnostic Training and Research Centre (AITRC), Department of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh. The cases were referring by different OPD's of Sir Sunderlal Hospital, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, with RA who fulfilled the American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) 2010 criteria ¹¹, were selected in a random manner. The study was approved by the appropriate ethics committee, and written informed consent was obtained from each patient before inclusion.

Statistical Analysis: Statistical analyses were conducted using SPSS for Windows (version 16.0). Descriptive statistics were obtained for all participants. Data has been presented in number and percentage. Step wise binary logistic regressions have been applied to correctly predicted percentage among study subjects.

RESULTS AND DISCUSSION: Table 1 provides the summary of demographic and clinical measures obtained from 290 clinically suspected patients. In present study 48 (16.6%) were RA positive. The burden of RA in the developing countries is enormous and almost similar to that described in the West ¹²⁻¹³. The prevalence of RA was 0.45% in India ¹⁴.

TABLE 1: PERCENT DISTRIBUTION OF STUDY SUBJECTS WITH RESPECT TO SOCIO-DEMOGRAPHIC AND ENVIRONMENTAL CHARACTERISTICS

S. No.	Variables		RA (%)	Non-RA (%)	Chi-Square value	p - value	
		≤ 20	8(16.7)	58(23.9)	2.85	0.415	
1	Age Group	21-40	24(50.0)	114(47.2)			
		41-60	13(27.1)	64(26.4)			
		>60	3(6.2)	6(2.5)			
2	Gender	Male	14(29.2)	96(39.7)	1.877	0.177	
		Female	34(70.8)	146(60.3)			
3	Food Habits	Veg.	21(43.8)	105(43.4)	0.002	0.963	
		Non-Veg.	27(56.2)	137(56.6)			
		Student	10(20.8)	84(34.7)			
4	Occupation	House wife	25(52.1)	94(38.8)			
		Farmer	3(6.3)	13(5.4)	4.949	0.293	
		Working Person	7(14.6)	42(17.4)			
		Other	3(6.2)	9(3.7)			
5	Type of	Sedentary	33(68.8)	99(40.9)	12.52	0.000	
	Occupation	Active	15(31.2)	143(59.1)			
6	Family	Yes	12(25)	25(10.3)	7.744	0.005	
	History	No	36(75)	217(89.7)			
7	Place of	Urban	16(33.3)	106(43.8)	1 001	0.1706	
	Residence	Rural	32(66.7)	136(56.2)	1.801	0.1796	

		≤ Primary	19(39.6)	61(25.2)		
8	Education	Primary to Inter	22(45.8)	95(39.3)	8.915	0.0116
		>Inter	7(14.6)	86(35.5)		
9	Milk	Yes	21(43.8)	126(52.1)	1 100	0.202
	consumption	No	27(56.3)	116(47.9)	1.108	0.292

Age and Sex: It has been observed that 47.6% of the clinically suspected cases fell in the middle age group of 21-40 years. Followed by age group 41-60 shows the second most predominance age group in study subject *i.e.* 77 (26.6%). 66 (22.8%) clinically suspected case belongs to the lower age group which belongs less than age twenty. Among all the clinically suspected cases the positivity rate is directly proportional to the age whereas according to Therapeutics in Malaysia. Bio-medicine News (2009) 15, RA affects about 0.5 per cent of adults between the ages of 25 and 50. Percentage of female clinically suspected cases that referred from OPDs was 62.1% and 37.9% male among the total study subjects. Noticed that positivity was also higher in female (70.81%) than male (29.2%).

Some previous study exhibit mixed pattern of prevalence according to the age-groups, such as, in the study of symmons (2002) ¹⁶, the incidence and prevalence of RA increase with age. Globally, the peak incidence of RA occurs between the ages of 55 and 64 years in women and 65-75 years in men and the age of onset is rising (Symmons, 2002) ¹⁷. According to Malaviya *et al.*, (1993) ¹⁸ that female were more prone to R.A. Lawrence (1998) ¹⁹ said that there are 2.5 times as many women as there are men with RA.

Rural Urban Background: The data were distributed in two category *i.e.* Urban, Rural. Results undoubtedly indicate the predomination of rural study subjects *i.e.* 57.9%. Most of the studies conclude that RA is more prevalent to the developed countries ¹⁸. RA is rare in undeveloped and rural areas ¹⁷, and the incidence of RA is higher among groups residing in urban areas. As a result, urbanization and air quality have been proposed as risk factors for the condition ²⁰⁻²¹ although reports of such an association are conflicting ²²⁻²³.

Education Status: Education programs employing behavioural interventions have small but significant effects on disability and depression, whereas programs focused solely on providing information do not demonstrate any significant effects or trends

²⁴. It has been observed that 66 (22.7%) subjects were graduate. Approximately educational status of 75% subjects was above the high school.

In addition, study in Sweden (the EIRA study), the risk of RA was studied vis-à-vis level of formal education; people without university degree had an increased risk of RA (relative risk = 1.4, 95% CI; 1.2-1.8) compared to those with a degree ²⁵. An Australian study demonstrated that the prevalence of RA was lowest among those who attended university and highest among those leaving school before 15 years of age ²⁶. Therefore, it appears that education programs need to provide information in combination with problem-solving skills and motivational activities ²⁷.

Occupations and their Nature: An association between type of occupation and the risk of developing RA has not been confirmed. There is some evidence of an association between organic dust exposure and the incidence of RA in men ²⁸. In the present house wife was more prone to as compare to the other occupation; about 32.4% clinically suspected cases belong to students in which only 10.6% had RA. Some studies have the importance of occupational evaluated determinants; an increased frequency of RA has been observed in several occupational categories ²⁹-

Food Habits: Many studies shown associations between RA and factors such as diet ³³⁻³⁵. Approximately fifty seven percent study subjects belong to the non-vegetarian and rest of them in vegetarian group. Wherein positivity in non vegetarian as compared to vegetarian was higher *i.e.* (56%). Total two ninety clinically suspected RA cases, 56.2% subjects were not taking milk directly or indirectly. And 43.8% of study subject were taking milk or any type of milk product including tea, coffee *etc.* Conflicting reports exist concerning coffee consumption as a possible risk factor for development of RA. A few reports have suggested that coffee is a risk factor ^{36, 37}.

Family History: In this study found that more that 87% of clinically suspected cases having no family history of RA. The familial nature of RA suggests that genetic risk factors play a role in susceptibility to RA ³⁸. Based on twin studies, the genetic contribution to RA susceptibility is estimated to be 60% ³⁹. Genetic variation in the human leukocyte antigen region is a contributing factor to the genetic risk of RA ⁴⁰. The disease also exhibits a higher concordance rate in identical twins than in fraternal twins ⁴¹.

Presence of Opportunistic Infections (Signs and Symptoms): In addition to present study distribution of positivity rate among the study subjects in **Table 2** provides the summary according to their signs and symptoms. However, in 10% to 15% of patients, the onset of disease is explosive, with polyarthritis, fever, lymphadenopathy, and splenomegaly developing over days to weeks ^{42, 43}.

The positivity rate was 29.8% among the suspects suffering from fever and 13.3% among those not suffering with fever. Positivity rate approximately 4 times higher in suspects suffering from dizziness than those who were not having dizziness Positivity rate was more than double in subjects suffering from tiredness than those not having 31.8% positivity was observed in suspects suffering from joint pain, 12.1% in those not having joint pain. Assessments in RA mainly look at joint inflammation ⁴⁴. Moreover in present study joint swelling, ankle swelling and neck pain positivity rate where approximately more than 2 times higher in suspects suffering from these signs and symptoms than those who were not suffering from these signs and symptoms. Out of total RA patient only 8.3% RA patient were having ankle swelling. The differences among them were statistically highly significant. 11.1% positivity was observed in suspects suffering from muscle pain, 16.9% in those not having muscle pain.

TABLE 2: PERCENT DISTRIBUTION OF STUDY SUBJECTS WITH RESPECT TO SIGN AND SYMPTOMS

Sign / Symptoms		RA (%)	Non-RA (%)	Chi-Square value	p - value	
Fever	Yes	17(29.8)	40(70.2)	9.049	0.005	
revei	No	31(13.3)	202(86.7)	9.049	0.003	
Dizziness	Yes	13(50.0)	13(50.0)	22.12	0.000	
Dizzilless	No	35(13.3)	229(86.7)	23.13	0.000	
Tirodnoss	Yes	33(45.8)	39(54.2)	12.52	0.000	
Tiredness	No	15(6.9)	209(93.1)	12.52	0.000	
Isint Dain	Yes	21(31.8)	45(68.2)	1//110	0.000	
Joint Pain	No	27(12.1)	197(87.9)	14.418	0.000	
Laint Cruallina	Yes	17(29.8)	40(70.2)	9.049	0.003	
Joint Swelling	No	31(13.3)	202(86.7)	9.049	0.003	
Ankle Swelling	Yes	4(80.0)	1(20.0)		0.003	
Alikie Swelling	No	44(15.4)	241(84.6)		0.003	
Back Pain	Yes	15(32.6)	31(67.4)	10.205	0.001	
Dack Falli	No	33(13.5)	211(86.5)	10.203	0.001	
Muscle Pain	Yes	2(11.1)	16(88.9)		0.747	
Muscle Palli	No	46(16.9)	226(83.1)		0.747	
Neck Pain	Yes	6(33.3)	12(66.7)	3.913	0.048	
	No 0(33.3)		` /			

Joints Involvement of the Study Subjects: RA is a chronic inflammatory disease characterized by joint swelling, joint tenderness, and destruction of synovial joints, leading to severe disability and premature mortality 45-48. The significant body ache with RA were Finger, Wrist, Toes, Shoulders, Neck, Back, Elbow, Ankle, Knee and Hips. Present study positivity rate was 41.3% among the suspects suffering from finger pain and 7.9% among those not suffering with finger pain. The course of established RA can range from mild disease to

rapidly progressive multisystem inflammation. About 70% of patients who have RA display a slow insidious disease onset; 20% have an intermediate onset; and 10% have a sudden acute onset. Patients predominantly complain of pain, stiffness, and swelling of their peripheral joints as the cardinal features of the disease. Physical examination of the joints reveals tenderness to palpation, synovial thickening, Joints effusion, and sometimes erythema and warmth.

TABLE 3: PERCENT DISTRIBUTION OF STUDY SUBJECTS WITH RESPECT TO INVOLVE JOINTS

Involve Joints		RA (%)	Non-RA (%)	Chi-Square value	p - value	
Finger	Yes	31(41.3)	44(58.7)	44.980	0.000	
Finger	No	17(7.9)	198(92.1)	44.900		
Wrist	Yes	33(55.0)	27(45.0)	80.968	0.000	
WIISL	No	15(13.3)	215(86.7)	00.700	0.000	
Toes	Yes	10(55.6)	8(44.4)	21.138	0.000	
1008	No	38(14.0)	234(86.0)	21.130	0.000	
Shoulders	Yes	16(30.2)	37(69.9)	8.732	0.003	
Siloulucis	No	32(13.5)	205(86.5)	0.732	0.003	
Neck	Yes	11(31.4)	24(68.6)	6.378	0.012	
TVCCK	No	37(14.5)	218(85.5)	0.570	0.012	
Back	Yes	21(25.6)	61(74.4)	6.791	0.013	
Dack	No	27(13.0)	181(87.0)	0.791	0.013	
Elbow	Yes	8(44.4)	10(56.6)	10.810	0.001	
LIOOW	No	40(14.7)	232(85.3)	10.010	0.001	
Ankle	Yes	17(39.5)	26(60.5)	19.308	0.000	
THIRIC	No	31(16.9)	216(83.1)	17.500	0.000	
Knee	Yes	40(22.3)	139(77.7)	11.369	0.001	
	No	8(7.2)	103(92.8)	11.507	0.001	
Hips	Yes	22(43.1)	29(56.9)	31.667	0.000	
тпрѕ	No	26(10.9)	213(89.1)	31.007		

TABLE 4: PERCENT DISTRIBUTION OF STUDY SUBJECTS WITH RESPECT TO INVESTIGATION PROFILE

Pland Test	9111120110					
Blood Test		RA (%)	Non-RA (%)	Chi-Square	p - value	
RF	+	37(77.1)	24(9.9)	108.79	P<0.001	
N	-	11(22.9)	218(91.1)	100.77	1 <0.001	
AntiCCP	+	36(75)	26(10.7)	98.39	P<0.001	
Alluccr	-	12(25)	216(91.3)	90.39	r<0.001	
CRP	+	45(93.8)	49(20.2)	00.70	D <0.001	
CKF	-	3(6.2)	193(79.8)	98.78	P<0.001	
CRP or AntiCCP	+	47(97.9)	65(26.9)	85.32	P<0.001	
CKF 01 AlluCCF	-	1(2.1)	177(73.1)	03.32	r<0.001	
CRP and AntiCCP	+	32(66.7)	7(2.9)	139.96	P<0.001	
CKF and AntiCCF	-	16(33.3)	235(93.1)	139.90	r<0.001	
RF or AntiCCP	+	48(100.0)	47(19.4)	118.07	P<0.001	
KI Of AffileCF	-	0(0.0)	195(80.6)	110.07	1<0.001	
RF and AntiCCP	+	25(89.6)	2(0.80)		P<0.001	
KI and AntiCCF	-	23(10.4)	240(99.20)		1<0.001	
RF or CRP	+	46(95.8)	60(24.8)	87.16	P<0.001	
KI OI CKI	-	2(4.2)	182(25.2)	67.10	1<0.001	
RF and CRP	+	34(70.8)	12(4.9)	130.24	P<0.001	
KI and CKI	-	14(29.2)	230(95.1)	130.24	1<0.001	
RF or AntiCCP or	+	48(100.0)	80(33.0)	72.80	P<0.001	
CRP	-	0(0.0)	162(67.0)	72.00	1 < 0.001	
RF and AntiCCP and	+	23(89.6)	3(90.5)		P<0.001	
CRP	-	25(10.4)	239(9.5)		r<0.001	

With longer duration of disease, there may be decreased range of motion with the much later possibility of joint ankylosis and subluxation. Initial involvement occurs in the upper extremities in over half of patients, with multiple joints affected in one-third and hand only involvement in about one-quarter of the cases. Joint symptoms are initially symmetric in 70% patients or become symmetric by 1 year after onset in 85%. The joints most commonly affected are the proximal inter-

phalangeal (PIP) and metacarpo-phalangeal (MCP) joints of the hand and wrist, followed by the metatarso-phalangeal (MTP) joints of the feet, ankles, and shoulders. According to Dr. Friederike Hammar (2010) ⁴⁹ RA usually begins subtly, with swelling, pain and problems with movement of the small and middle finger joints, as well as with unspecific symptoms like rapid fatigue and general weakness. If the disease is not stopped it leads to complete destruction of the joints.

TABLE 5: FORWARD STEPWISE LIKELIHOOD MODEL WITH CORRECTLY PREDICTED PERCENTAGE

Reprofice Reproduct Repr	TABLE 5: FORWARD STEPWISE LIKELIHOOD MODEL WITH CORRECTLY PREDICTED PERCENTAGE									
Intermediate the mode the m	Forward	Variable	Regression	Standard	-2log	Nagelkerke	Correctly predicted %		$\chi^2/$ p-	
Time	stepwise	included in	coefficient (B)	error (B)	likelihood	R^2*100	D.4	Non	Orronall	value
Constant	likelihood model	the model					KA	-RA	Overali	
II Step	I Step	RF	-3.419	.405	170.023	45.1	90.1	77.1	87.9	90.22
Manual		Constant	.433	.262						P<0.001
Mil Step	II Step	RF	-4.364	.761	105.823	69.7	99.2	52.1	91.4	154.42
III Step	•	AntiCCP	-4.185	.761						P<0.001
III Step										
RF	III Step				84.923	76.6	95.9	87.5	94.5	175.32
AntiCCP	1	RF								
IV Step		AntiCCP	-4.136							
Tiredness										
Wrist	IV Step				71.335	80.8	98.8	68.8	93.8	188.91
RF	1									
NaticCP										
V Step										
V Step										
Fingers 2.024 .775 Wrist 2.444 .729 RF	V Step				63.540	83.1	97.5	87.5	95.9	196.71
Wrist	, step				00.0	00.1	,,,,	07.10	, , , ,	
RF										1 (0.001
AntiCCP										
VI Step										
VI Step										
Fingers 2.899 9.82 Wrist 2.696 .811 Hips 2.510 .945 RF -4.412 1.029 AntiCCP 4.245 .999 Constant -2.21 1.083 Tiredness 2.066 .878 48.640 87.4 98.3 89.6 96.9 211.61 Fingers 3.013 1.077 Wrist 3.234 .938 VII Step Toes 3.340 1.430 Hips 2.610 1.005 RF -5.031 1.192 AntiCCP 4.359 1.075 Constant534 1.132 Tiredness 2.504 1.019 44.271 88.7 98.3 87.5 96.6 215.97 Fingers 2.990 1.131 Wrist 3.782 1.086 Toes 4.423 1.606 VIII Step Back 1.989 1.040 Hips 2.883 1.091 RF -5.530 1.346 AntiCCP -4.305 1.159 Constant -1.589 1.423 Tiredness 2.375 1.105 39.322 90.0 98.8 91.7 97.6 220.92 Fingers 2.989 1.141 Toes 4.171 1.791 Back 2.442 1.191 HX Step Back 2.442 1.191 HX Step Back 2.442 1.191 RF -5.550 1.241 Toes 4.171 1.791 RF -4.666 1.393 AntiCCP -3.402 1.1071 RF -4.666 1.393 AntiCCP -2.249 1.103	VI Sten				54 788	85.7	97.9	91.7	96.9	205.46
Wrist	VISICP				34.766	05.7)1.)	71.7	70.7	
Hips										1 <0.001
RF										
AntiCCP										
Constant Tiredness 2.066 .878 48.640 87.4 98.3 89.6 96.9 211.61										
VII Step										
VII Step					18 610	97 1	08.3	80.6	06.0	211.61
VII Step VII Step					40.040	67.4	70.3	69.0	90.9	
VII Step										1<0.001
VII Step Hips 2.610 1.005 RF -5.031 1.192 AntiCCP -4.359 1.075 Constant534 1.132 Tiredness 2.504 1.019 44.271 88.7 98.3 87.5 96.6 215.97 Fingers 2.990 1.131 Wrist 3.782 1.086 Toes 4.423 1.606 VIII Step Back 1.989 1.040 Hips 2.883 1.091 RF -5.530 1.346 AntiCCP -4.305 1.159 Constant -1.589 1.423 Tiredness 2.375 1.105 39.322 90.0 98.8 91.7 97.6 220.92 Fingers 2.989 1.144 Wrist 3.770 1.241 Toes 4.171 1.791 Back 2.442 1.191 Hips 2.552 1.071 RF -4.666 1.393 AntiCCP -3.402 1.175 CRP -2.249 1.103										
RF	VII Step									
AntiCCP										
Constant Tiredness 2.504 1.019 44.271 88.7 98.3 87.5 96.6 215.97 Fingers 2.990 1.131 Wrist 3.782 1.086 Toes 4.423 1.606 VIII Step Back 1.989 1.040 Hips 2.883 1.091 RF -5.530 1.346 AntiCCP -4.305 1.159 Constant -1.589 1.423 Tiredness 2.375 1.105 39.322 90.0 98.8 91.7 97.6 220.92 Fingers 2.989 1.144 Wrist 3.770 1.241 Toes 4.171 1.791 Back 2.442 1.191 Hips 2.552 1.071 RF -4.666 1.393 AntiCCP -3.402 1.175 CRP -2.249 1.103										
Tiredness 2.504 1.019 44.271 88.7 98.3 87.5 96.6 215.97 Fingers 2.990 1.131 Wrist 3.782 1.086 Toes 4.423 1.606 VIII Step Back 1.989 1.040 Hips 2.883 1.091 RF -5.530 1.346 AntiCCP -4.305 1.159 Constant -1.589 1.423 Tiredness 2.375 1.105 39.322 90.0 98.8 91.7 97.6 220.92 Fingers 2.989 1.144 Wrist 3.770 1.241 Toes 4.171 1.791 Back 2.442 1.191 Hips 2.552 1.071 RF -4.666 1.393 AntiCCP -3.402 1.175 CRP -2.249 1.103										
Fingers 2.990 1.131 Wrist 3.782 1.086 Toes 4.423 1.606 VIII Step Back 1.989 1.040 Hips 2.883 1.091 RF -5.530 1.346 AntiCCP -4.305 1.159 Constant -1.589 1.423 Tiredness 2.375 1.105 39.322 90.0 98.8 91.7 97.6 220.92 Fingers 2.989 1.144 Wrist 3.770 1.241 Toes 4.171 1.791 Back 2.442 1.191 Hips 2.552 1.071 RF -4.666 1.393 AntiCCP -3.402 1.175 CRP -2.249 1.103					44.271	00.7	00.2	07.5	06.6	215.07
Wrist 3.782 1.086 Toes 4.423 1.606 VIII Step Back 1.989 1.040 Hips 2.883 1.091 RF -5.530 1.346 AntiCCP -4.305 1.159 Constant -1.589 1.423 Tiredness 2.375 1.105 39.322 90.0 98.8 91.7 97.6 220.92 Fingers 2.989 1.144 Wrist 3.770 1.241 Toes 4.171 1.791 Back 2.442 1.191 Hips 2.552 1.071 RF -4.666 1.393 AntiCCP -3.402 1.175 CRP -2.249 1.103					44.271	88.7	98.3	87.5	90.0	
VIII Step Toes										P<0.001
VIII Step Back										
Hips 2.883 1.091 RF -5.530 1.346 AntiCCP -4.305 1.159 Constant -1.589 1.423 Tiredness 2.375 1.105 39.322 90.0 98.8 91.7 97.6 220.92 Fingers 2.989 1.144 Wrist 3.770 1.241 Toes 4.171 1.791 Back 2.442 1.191 Hips 2.552 1.071 RF -4.666 1.393 AntiCCP -3.402 1.175 CRP -2.249 1.103	VIII C									
RF -5.530 1.346 AntiCCP -4.305 1.159 Constant -1.589 1.423 Tiredness 2.375 1.105 39.322 90.0 98.8 91.7 97.6 220.92 Fingers 2.989 1.144 Wrist 3.770 1.241 Toes 4.171 1.791 Back 2.442 1.191 Hips 2.552 1.071 RF -4.666 1.393 AntiCCP -3.402 1.175 CRP -2.249 1.103	VIII Step									
AntiCCP -4.305 1.159 Constant -1.589 1.423 Tiredness 2.375 1.105 39.322 90.0 98.8 91.7 97.6 220.92 Fingers 2.989 1.144 Wrist 3.770 1.241 Toes 4.171 1.791 Back 2.442 1.191 Hips 2.552 1.071 RF -4.666 1.393 AntiCCP -3.402 1.175 CRP -2.249 1.103										
Constant -1.589 1.423 Tiredness 2.375 1.105 39.322 90.0 98.8 91.7 97.6 220.92 Fingers 2.989 1.144 Wrist 3.770 1.241 Toes 4.171 1.791 Back 2.442 1.191 Hips 2.552 1.071 RF -4.666 1.393 AntiCCP -3.402 1.175 CRP -2.249 1.103										
Tiredness 2.375 1.105 39.322 90.0 98.8 91.7 97.6 220.92 Fingers 2.989 1.144 Wrist 3.770 1.241 Toes 4.171 1.791 Back 2.442 1.191 Hips 2.552 1.071 RF -4.666 1.393 AntiCCP -3.402 1.175 CRP -2.249 1.103										
Fingers 2.989 1.144 P<0.001 Wrist 3.770 1.241 Toes 4.171 1.791 Back 2.442 1.191 Hips 2.552 1.071 RF -4.666 1.393 AntiCCP -3.402 1.175 CRP -2.249 1.103										
Wrist 3.770 1.241 Toes 4.171 1.791 Back 2.442 1.191 Hips 2.552 1.071 RF -4.666 1.393 AntiCCP -3.402 1.175 CRP -2.249 1.103					39.322	90.0	98.8	91.7	97.6	
IX Step Toes 4.171 1.791 Back 2.442 1.191 Hips 2.552 1.071 RF -4.666 1.393 AntiCCP -3.402 1.175 CRP -2.249 1.103										P<0.001
IX Step Back 2.442 1.191 Hips 2.552 1.071 RF -4.666 1.393 AntiCCP -3.402 1.175 CRP -2.249 1.103										
Hips 2.552 1.071 RF -4.666 1.393 AntiCCP -3.402 1.175 CRP -2.249 1.103										
RF -4.666 1.393 AntiCCP -3.402 1.175 CRP -2.249 1.103	IX Sten									
AntiCCP -3.402 1.175 CRP -2.249 1.103	121 оюр									
CRP -2.249 1.103										
Constant -1.789 1.571										
Constant -1.707 1.571		Constant	-1.789	1.571						

With periodic flare-ups, the disease marches inexorably onward, affecting more and more joints. Positivity rate was approximately more than 2 times higher in suspects suffering from wrist involvement than those who were not having problem in wrist. Positivity rate was approximately one-fourth in subjects suffering from toes pain than those not having any difficulties in toes, 30.2% positivity was observed in suspects suffering from shoulder involvement, 13.5% in those not suffering from shoulder problem.

Positivity rate in involvement of neck and back where approximately more than 2 times higher in suspects suffering from neck and back problem than those who were not suffering from neck and back problem. Out of total RA patient only 16.7% RA patient were having difficulty in elbow. 39.5% positivity was observed in suspects suffering from ankle problem, 16.9% in those not having ankle problem. Maximum percentages of RA patients having knee difficulty i.e. 83.3%. Out of total hips affected subjects 43.1% were RA patients. The differences among them were statistically highly significant (P < 0.001). In Indian context, reason behind majority in knee difficulties was reported by Kumar et al., (2002) 50 that sitting cross-legged on the floor is a standard practice in India.

Even the higher socio-economic strata of the society practice it in social or religious assemblies. This posture requires acute flexion of the knees besides abduction, flexion and external rotation of the hip joints. A similar set of joint movements is needed for another important activity in the Indian population, *i.e.* squatting in the toilet. Inability to perform either of these two activities means a major functional disability.

Investigation Profile of the Study Subjects: The presence of "rheumatoid factor" (RF) was identified in patients with RA over 50 years ago ⁵¹; assays for RF remain one of the ACR classification criteria for RA. 61 (21.0%) out of 290 subjects found positive for RF, and out of 61 subjects, 37 had RA. This compared with 62 / 290 (21.4%) subjects found positive for anti-CCP. In which 36 had RA. Besides, over the past few years, many studies have evaluated the diagnostic performance of anti-CCP on a variety of diagnostic platform ⁵²⁻

High levels of C-reactive protein (CRP) are also indicators of active inflammation. Like the ESR, a high result does not indicate what part of the body is inflamed, or what is causing the inflammation 57 . Whereas in present study 94 (32.4%) out of 290 subjects observed positive for acute phase reactant CRP and 93.8% positivity of RA out of total RA patients. The differences observed among the various blood tests and positivity rate was found statistically highly significant (p < 0.001).

If considered combinations of serology tests and acute phase reactant CRP or AntiCCP, CRP and AntiCCP, RF or AntiCCP, RF and AntiCCP, RF or CRP, RF and CRP, RF or AntiCCP or CRP and RF and AntiCCP and CRP. It was observed that RF AntiCCP and CRP showed minimum and percentage of RA patients from total RA patients. Whereas RF or AntiCCP and RF or AntiCCP or CRP both the combination had 100% outcome. The differences observed among the combination of various blood tests and positivity rate was found statistically highly significant (p<0.001). Detection of anti-CCP is very useful for the diagnosis of RA, in fact even RF also very useful for diagnosis of RA and combination of testing for both RF and anti-CCP may be even more useful in comparison to individual test.

Early treatment of RA is important as it can prevent irreversible damage of the joints. Despite the strong diagnostic value of anti-CCP and RF, there is strong demand for novel serological biomarkers to further improve the early diagnostic of this abundant disease ⁵⁸.

Multivariate Technique: From the brief account of discussion on observation and results of multivariate techniques are demonstrated below, such techniques are important for they make it possible to encompass all the data from an investigation in one analysis. They in fact result in a clearer and better account of the research effort than do the piecemeal analyses of portions of data. According to van der Helm-van Mil AH *et al.*, (2007), using regression analysis the variables that were independent predictors for the development of RA was selected. This resulted in the construction of prediction rule. In present study using step wise binary logistic regression, RA patients correctly categorized according to their positivity status.

In the first step blood test of RF of subjects has categorized 90.1% and 77.1% RA and non-RA respectively. By including the blood test of AntiCCP the percentage was increased up to 99.2% and 52.1%, in the third step by adding symptom of tiredness, these percentages were 95.9% and 87.5% correctly. At the fourth step by including the involvement of wrist joint has categorized the 98.8% RA and 68.8% non RA. In the fifth step involvement of finger joint of subjects has categorized 97.5% and 87.5% RA and non-RA respectively.

By including the involvement of hip joint the percentage was increased up to 97.9% and 91.7% in the seventh step by adding involvement of toe joint, these percentages were 98.3% and 89.6% correctly. At the eight step by including the attachment of back pain has categorized the 98.3% RA and 87.5% non RA. By including the blood test of CRP in ninth step the percentage was increased up to 98.8% and 91.7%.

CONCLUSION: The finding of this study illustrates that there is no single variable or screening test is suitable to diagnose the RA disease. Females are more prone for this disease as compared to male. The suspected cases having the family history had more chances to become diseased as compared to cases not having the family history of RA. This disease also affects the quality of life *i.e.* disability increases.

ACKNOWLEDGEMENT: I would like to acknowledge Prof. T. B. Singh and Prof. Usha for proof reading, valuable suggestions, assistance in reviewing and providing recommendations for enhancement of this paper.

REFERENCES:

- Van Venrooij WJ, Zendman AJ and Pruijn GJ: Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis, Autoimmun Rev 2006; 6: 37–41.
- 2. Gabriel JT, Youinou P and SarauxA: The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis. Autoimmunity Reviews 2010; 9: 288–292.
- Gregersen PK, Silver J and Winchester RJ: The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205–13.
- Bräuer W, Merkesdal S and Mau W: Langzeitverlauf und Prognose der Erwerbstätigkeit der chronischen Polyarthritis [Long-term follow-up and prognosis of work

capacity in the early stage of chronic polyarthritis]

E-ISSN: 0975-8232; P-ISSN: 2320-5148

- German. Z Rheumatologie 2002; 61: 426-434,
 5. WHO: The Burden of Musculoskeletal Conditions at the start of the Millenium. World Health Organ Tech Rep. Ser 2003: 919: 1(10): 1-218.
- Hemminki K, Li X, Sundquist J and Sundquist K: Familial associacions of rheumatoid arthritis with autoimmune diseases and related conditions. Arthritis Rheum 2009; 60(3): 661-8.
- Padyukov L, Silva C, Stolt P, Alfredsson L and Klareskog L: for the Epidemiological Investigation of Rheumatoid Arthritis Study Group. A Gene-Environment Interaction Between Smoking and Shared Epitope Genes in HLA-DR Provides a High Risk of Seropositive Rheumatoid Arthritis. Arthritis Rheum. 2004; 50(10): 3085-92.
- Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, de Bakker PI, Gabriel SB, Mirel DB, Ivinson AJ, Pericak-Vance MA, Gregory SG, Rioux JD, McCauley JL, Haines JL, Barcellos LF, Cree B, Oksenberg JR and Hauser SL: Risk alleles for multiple sclerosis identified by a genomewide study. International Multiple Sclerosis Genetics Consortium. N Engl J Med. 2007; 357(9): 851-62.
- D'Netto MJ, Ward H, Morrison KM, Ramagopalan SV, Dyment DA, DeLuca GC, Handunnetthi L, Sadovnick AD and Ebers GC: Risk alleles for multiple sclerosis in multiplex families. Neurology 2009.
- Padyukov L, Silva C, Stolt P, Alfredsson L and Klareskog L: A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum. 2004; 50: 3085-92.
- Aletaha D, Neogi T, Silman AJ et al.: Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2010; 69: 1580– 8.
- 12. Chopra A and Abdel N: Epidemiology of rheumatic musculoskeletal disorders in the developing world. Best Prac Res ClinRheumatol 2008; 22: 583-604.
- 13. Davatchi F, Tehrani Banihashemi A, Gholami J *et al.*: The prevalence of musculoskeletal complaints in a rural area in Iran: a WHO-ILAR COPCORD study (stage1, rural study) in Iran. ClinRheumatol 2009; 28: 1267-1274.
- Vaijayanti J and Chopra A: Is there an urban-rural divided? Population surveys of rheumatic musculoskeletal disorder in the pune region of India using the COPCORD Bhigwan model. J Rheumatol 2009; 36: 614-622.
- 15. Rheumatoid Arthritis Therapeutics in Malaysia. Biomedicine News, 31 March 2009.
- 16. Symmons D, Turner G, Webb R, Aslen P, Barret E, Lunt M *et al.*: The prevalence of rheumatoid arthritis in the United Kingdom; new estimates for a new century. Rheumatology (Oxford) 2002; 41(7): 793-800.
- 17. Symmons D: Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res ClinRheumatol 2002; 16(5): 707-22.
- 18. Malaviya, AN, Kapoor, SK, Singh, RB *et al.*: Prevalence of rheumatoid arthritis in the adult Indian population. Rheumatology International 1993; 13: 131–134.
- Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson David T, Giannini EH, Heyse SP, Hirsch R, Hochberg Marc C, Hunder GG, Liang MH, Pillemer SR, Steen, VD and Wolfe F: Estimates of the Prevalence of Arthritis and Selected Musculoskeletal Disorders in the United States. Arthritis and Rheumatism 1998; 41(5): 778-799.

- Bankhead C, Silman A, Barrett B, Scott D and Symmons D: Incidence of rheumatoid arthritis is not related to indicators of socioeconomic deprivation. J Rheumatol. Dec 1996; 23(12): 2039–2042.
- Solomon L, Robin G and Valkenburg HA: Rheumatoid arthritis in an urban South African Negro population. Annals of the Rheumatic Diseases 1975; 34(2): 128-135.
- MacGregor AJ, Riste LK, Hazes JMW and Silman AJ: Low prevalence of rheumatoid arthritis in Black-Caribbeans compared with Whites in inner city Manchester. Annals of the Rheumatic Diseases 1994; 53(5): 293-297.
- 23. Lau E, Symmons D, Bankhead C *et al.*: Low prevalence of rheumatoid arthritis in the urbanized Chinese of Hong Kong. J Rheumatol 1993; 20: 1133–7.
- 24. Riemsma R, Taal E, Kirwan J and Rasker J: Systematic review of rheumatoid arthritis patient education. Arthritis Care Res. 2004; 51(6): 1045-59.
- Bengtsson C, Nordmark B, Klareskog L et al.: Sociao economic status and the risk of developing rheumatoid arthritis: Results from the Swedish EIRA study. Ann Rheum Dis 2005; 64(11): 1588-1594.
- Hill CL, Parsons J, Taylor A and Leach G: Health related quality of life in a population sample with arthritis. Journal of Rheumatology 1999; 26(9): 2029-2035.
- 27. Dieppe P and Brandt K: What is important in treating osteoarthritis? Whom should we treat and how should we treat them? Rheum Dis Clin N Am. 2003; 29: 687–716.
- 28. Olsson A, Skogh T, Axelson O and Wingren G: Occupations and exposures in the work environment as determinants for rheumatoid arthritis. Occup Environ Med. 2004; 61(3): 233-8.
- Hellgren L: The prevalence of rheumatoid arthritis in occupational groups. Acta Rheum Scand 1970; 16: 106– 13
- Lundberg I, Alfredsson L, Plato N et al.: Occupation, occupational exposure to chemical and rheumatological disease a register- based cohort study. Scand J Rheumatologist 1994; 23(6): 305-310.
- Koskela RS, Klockars M and Ja¨rvinen E: Mortality and disability among cotton mill workers. Br J Ind Med. 1990; 47: 384–91.
- 32. Klockars M, Koskela RS, Ja"rvinen E *et al.*: Silica exposure and rheumatoid arthritis: a follow-up study of granite workers 1940–81. BMJ 1987; 294: 997–1000.
- 33. Pedersen M, Stripp C, Klarlund M, Olsen SF, Tjonneland AM and Frisch M: Diet and risk of rheumatoid arthritis in a prospective cohort. J Rheumatol 2005; 32: 1249-1252.
- 34. Shapiro JA, Koepsell TD, Voigt LF, Dugowson CE, Kestin M and Nelson JL: Diet and rheumatoid arthritis in women: a possible protective effect of fish consumption. Epidemiology 1996; 7: 256-263.
- 35. Pattison DJ, Symmons DPM, Lunt M, Welch A, Luben R, Bingham SA, Khaw KT, Day NE and Silman AJ: Dietary risk factors for the development of inflammatory polyarthritis: evidence for a role of high level of red meat consumption. Arthritis Rheum 2004; 50: 3804-3812.
- Heliövaara M, Aho K, Knekt P, Impivaara O, Reunanen A and Aromaa A: Coffee consumption, rheumatoid factor, and the risk of rheumatoid arthritis. Ann Rheum Dis 2000; 59: 631-635.
- 37. Mikuls TR, Cerhan JR, Criswell LA, Merlino L, Mudano AS, Burma M, Folsom AR and Saag KG: Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum 2002; 46: 83-91.

- 38. Gabriel SE: The epidemiology of rheumatoid arthritis. Rheum. Dis. Clin. North Am 2001; 27: 269-281.
- 39. MacGregor AJ, Snieder H, Rigby AS *et al.*: Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000; 43: 30.
- Stastny P: Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978; 298: 869-871
- 41. MacGregor A, Ollier W, Venkovsky J *et al.*: Rheumatoid factor isotopes in monozygotic and dizygotic twins discordant for rheumatoid arthritis. Journal of Rheumatology 1995; 22: 2203–7.
- Firestein GS: Etiology and pathogenesis of rheumatoid arthritis. In: Ruddy S, Harris E, Sledge C (eds): Kelly's Textbook of Rheumatology. 6th ed. Philadelphia: WB Saunders 2001; 921-966.
- 43. Kirkham BW, Lassere MN, Edmonds JP et al.: Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis. A two-year prospective study (the DAMAGE Study Cohort). Arthritis Rheum 2006; 54: 1122-1131.
- 44. Dougados M, Aletaha D and Van Riel P: Disease activity measures for rheumatoid arthritis. Clin Exp Rheumatol 2007; 25(5S-46): S22-9.
- 45. Scott DL, Coulton BL, Symmons DPM and Popert JA: Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet I 1987; 1108-11.
- Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ and Fries JF: Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986; 29: 706-14.
- 47. Pincus T, Brooks RH and Callahan LF: Prediction of longterm mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Int Med 1994; 120: 26-34.
- 48. Isomäki H: Long-term outcome of rheumatoid arthritis. Scand J Rheumatol 1992; 21: 3-8.
- Friederike H: Genetics of Rheumatoid Arthritis Susceptibility 2010. http://autoimmunityblog.com/2010/07 /21/incidence- of- rheumatoid- arthritis- facts- andfigures-about-ra/.
- 50. Kumar AN, Malaviya AP and Singh R: Validation of an Indian version of the Health Assessment Questionnaire in patients with rheumatoid arthritis, Rheumatology (Oxford) 2002; 41(12): 1457-9.
- 51. Rose HM, Ragan C, Pearce E and Lipman MO: Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. Proc Soc Exp Biol Med 1949; 68: 1–6.
- 52. Vander Cruyssen B, Nogueira L, Van Praet J, Deforce D, Elewaut D, Serre G *et al.*: Do all anti-citrullinated protein/peptide antibody tests measure the same? Evaluation of discrepancy between anti-citrullinated protein/peptide antibody tests in patients with and without rheumatoid arthritis. Ann Rheum Dis 2008; 67: 542–6.
- 53. Bizzaro N, Tonutti E, Tozzoli R and Villalta D: Analytical and diagnostic characteristics of 11 2nd and 3rd generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem 2007; 53: 1527–33.
- 54. Santiago M, Baron M, Miyachi K, Fritzler MJ, Abu-Hakima M, Leclercq S *et al.*: A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. ClinRheumato 2008; 27: 77–83.
- 55. Correia ML, Carvalho S, Fortuna J and Pereira MH: Comparison of three anti-CCP antibody tests and

- rheumatoid factor in RA and control patients. Clin Rev Allergy Immunol 2008; 34: 21–5.
- Jaskowski TD, Hill HR, Russo KL, Lakos G, Szekanecz Z and Teodorescu M: Relationship between rheumatoid factor isotypes and IgG anti-cyclic citrullinated peptide antibodies. J Rheumatol 2010; 37: 1582–8.
- University of Maryland Medical Center, Rheumatoid arthritis, 2013.
 http://umm.edu/health/medical/reports/articles/rheumatoid-arthritis
- Trouw LA and Mahler M: Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmunity Reviews 2012; 12: 318–322.

59. Van der Helm-van Mil AH, le Cessie S, Van Dongen H, Breedveld FC, Toes RE and Huizinga TW: A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 2007; 56(2): 433-40.

How to cite this article:

Ahmad A, Singh TB, Usha and Kumar N: Analysis of variables involve in rheumatoid arthritis diagnosis using logistic regression. Int J Pharm Sci & Res 2018; 9(1): 123-32. doi: 10.13040/JJPSR.0975-8232.9(1).123-32.

All © 2013 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to **ANDROID OS** based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)